JOHN-PAUL GOMEZ: Open Payments
NPI 1811958366 · BETHLEHEM, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$465 in 23 payments from 9 companies in 2025. Trend: 2023 $448 · 2024 $709 · 2025 $465
Food & beverage: $465
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 9 | $141 |
| Neurocrine BioSciences, Inc. | 2 | $101 |
| Teva Pharmaceuticals USA, Inc. | 5 | $95 |
| Janssen Pharmaceuticals, Inc | 2 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Alkermes, Inc. | 1 | $14 |
Products named: COBENFY, INGREZZA, AUSTEDO XR, INVEGA SUSTENNA, UZEDY, CAPLYTA, ABILIFY ASIMTUFII, FANAPT.
Industry payments across PA — which companies pay providers there.
